Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells $21,750.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $72.50, for a total value of $21,750.00. Following the sale, the chief operating officer owned 54,324 shares in the company, valued at approximately $3,938,490. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Stock Down 1.8%

Shares of NASDAQ IRON traded down $1.36 during trading on Tuesday, reaching $73.14. 729,507 shares of the stock were exchanged, compared to its average volume of 612,517. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of -11.05 and a beta of 0.93. The business’s 50-day moving average price is $68.99 and its 200 day moving average price is $70.77. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, equities analysts forecast that Disc Medicine, Inc. will post -6.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Disc Medicine

Several large investors have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd acquired a new position in Disc Medicine in the fourth quarter worth about $33,000. Aster Capital Management DIFC Ltd acquired a new stake in Disc Medicine during the third quarter valued at approximately $38,000. KBC Group NV bought a new position in Disc Medicine during the 4th quarter worth approximately $80,000. Persistent Asset Partners Ltd acquired a new position in shares of Disc Medicine in the 4th quarter worth approximately $141,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Disc Medicine by 36.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after acquiring an additional 490 shares in the last quarter. Institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

IRON has been the topic of a number of analyst reports. Wells Fargo & Company lifted their target price on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Morgan Stanley raised their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. Wedbush restated an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Finally, Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus price target of $105.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.